Standard Dosage Regimens of Broad-Spectrum Beta-lactams are Inadequate to Treat "Difficult-to-Treat" Pathogens in Obese Non-critically Ill Patients
Maya Hites(Université Libre de Bruxelles), Frédérique Jacobs(Université Libre de Bruxelles), Fleur Wolff(Université Libre de Bruxelles), Rudy Surin(Erasmus Hospital), Evelyne Maillart(Erasmus Hospital), Guillaume Deprez(Université Libre de Bruxelles), Fabio Taccone(Erasmus Hospital), J Araci, Frédéric Cotton(Université Libre de Bruxelles)
Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles)
September 1, 2012
Cited by 0
Related Papers
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial
|The Lancet|2007|689
Deep Dermatophytosis and Inherited CARD9 Deficiency
|New England Journal of Medicine|2013|403
Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock
|Critical Care|2010|372
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial
|The Lancet Infectious Diseases|2021|344
Impact of Infectious Diseases Specialists and Microbiological Data on the Appropriateness of Antimicrobial Therapy for Bacteremia
|Clinical Infectious Diseases|1999|266